Aytu BioScience
Yahoo Finance • 8 days ago
Aytu outlines EXXUA launch targeting $22B MDD market while streamlining ADHD portfolio
Earnings Call Insights: Aytu BioPharma (AYTU) Q4 2025 MANAGEMENT VIEW * CEO Joshua Disbrow highlighted "the strong financial performance during the recent fiscal year and perhaps more importantly, the upcoming launch of EXXUA, which we... Full story
Yahoo Finance • 8 days ago
Aytu BioPharma GAAP EPS of -$2.93 misses by $2.88, revenue of $15.1M misses by $2.82M
* Aytu BioPharma press release [https://seekingalpha.com/pr/20242010-aytu-biopharma-reports-fiscal-2025-full-year-and-fourth-quarter-operational-and-financial] (NASDAQ:AYTU [https://seekingalpha.com/symbol/AYTU]): Q4 GAAP EPS of -$2.93 m... Full story
Yahoo Finance • 9 days ago
Aytu BioPharma FQ4 2025 Earnings Preview
* Aytu BioPharma (NASDAQ:AYTU [https://seekingalpha.com/symbol/AYTU]) is scheduled to announce FQ4 earnings results on Tuesday, September 23rd, after market close. * The consensus EPS Estimate is -$0.06 [https://seekingalpha.com/symbol... Full story
Yahoo Finance • 2 months ago
Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition
Aytu BioPharma, Inc. (NASDAQ:AYTU) is one of the best high-return penny stocks to buy now. On July 1, Lake Street Capital Markets initiated coverage on Aytu Biosciences (NASDAQ:AYTU) with a Buy rating and an $8.00 price target, citing stro... Full story
Yahoo Finance • 4 months ago
Aytu BioPharma to commercialise Exxua for MDD in the US
Aytu BioPharma has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua (gepirone) extended-release tablets, a new antidepressant, to the US market for major depressive disorder (MDD). Exxua, developed by... Full story
Yahoo Finance • 2 years ago
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administration Which, if Approved, Enables the Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturin... Full story
Yahoo Finance • 2 years ago
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Interest Only Period on Avenue Capital Term... Full story
